Literature DB >> 28110669

In vitro screening and in silico validation revealed key microbes for higher production of significant therapeutic enzyme l-asparaginase.

Archana Vimal1, Awanish Kumar2.   

Abstract

l-asparaginase is an enzyme of medical prominence and reputable as a chemotherapeutic agent. It also has immense potential to cure autoimmune and infectious diseases. The vast application of this enzyme in healthcare sector increases its market demand. However, presently the huge market demand is not achieved completely. This serves the basis to explore better producer microbial strains to bridge the gap between huge demand and supply of this therapeutic enzyme. The present study deals with the successful screening of potent microorganisms producing l-asparaginase. 47 microorganisms were screened including bacteria, fungi, and yeasts. Among all, Penicillium lilacinum showed the highest enzyme activity i.e., 39.67 IU/ml. Shigella flexneri has 23.21 IU/ml of enzyme activity (highest among all the bacterial strain tested). Further, the 3-D structure of l-asparaginase from higher producer strains was developed and validated in silico for its activity. l-asparagine (substrate for l-asparaginase) was docked inside the binding pocket of P. lilacinum and S. flexneri. Docking score for the most common substrate l-asparagine is -6.188 (P. lilacinum), -5.576 (S. flexneri) which is quite good. Moreover, the chemical property of the binding pocket revealed that amino acid residues Phe 243, Gln 260, Gly 365, Asp 386 in P. lilacinum and residues Asp 181, Thr 318, Asn 320 in S. flexneri have an important role in H-bonding. The in silico results supports and strengthen the wet lab results. The outcome obtained motivates to take the present study result from lab to industry for the economic/massive production of this enzyme for the diverse therapeutic application.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Higher producer strains; In silico validation; In vitro screening; Therapeutics; l-asparaginase

Mesh:

Substances:

Year:  2016        PMID: 28110669     DOI: 10.1016/j.enzmictec.2016.12.001

Source DB:  PubMed          Journal:  Enzyme Microb Technol        ISSN: 0141-0229            Impact factor:   3.493


  6 in total

Review 1.  What makes a good new therapeutic L-asparaginase?

Authors:  Angela Beckett; David Gervais
Journal:  World J Microbiol Biotechnol       Date:  2019-09-24       Impact factor: 3.312

2.  l-Asparaginase: a feasible therapeutic molecule for multiple diseases.

Authors:  Archana Vimal; Awanish Kumar
Journal:  3 Biotech       Date:  2018-05-28       Impact factor: 2.406

3.  Optimized chromogenic dyes-based identification and quantitative evaluation of bacterial l-asparaginase with low/no glutaminase activity bioprospected from pristine niches in Indian trans-Himalaya.

Authors:  Virender Kumar; Subhash Kumar; Sanyukta Darnal; Vijeta Patial; Anju Singh; Vikas Thakur; Sanjay Kumar; Dharam Singh
Journal:  3 Biotech       Date:  2019-06-20       Impact factor: 2.406

4.  Characterization of novel L-asparaginases having clinically safe profiles from bacteria inhabiting the hemolymph of the crab, Scylla serrata (Forskål, 1775).

Authors:  V P Lailaja; T G Sumithra; K J Reshma; V N Anusree; P V Amala; T G Kishor; N K Sanil
Journal:  Folia Microbiol (Praha)       Date:  2022-02-09       Impact factor: 2.099

Review 5.  Overview of the structure, side effects, and activity assays of l-asparaginase as a therapy drug of acute lymphoblastic leukemia.

Authors:  Nanxiang Wang; Wenhui Ji; Lan Wang; Wanxia Wu; Wei Zhang; Qiong Wu; Wei Du; Hua Bai; Bo Peng; Bo Ma; Lin Li
Journal:  RSC Med Chem       Date:  2022-01-12

6.  Massive annotation of bacterial L-asparaginases reveals their puzzling distribution and frequent gene transfer events.

Authors:  Andrzej Zielezinski; Joanna I Loch; Wojciech M Karlowski; Mariusz Jaskolski
Journal:  Sci Rep       Date:  2022-09-22       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.